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During the 40th Annual Meeting of The Toxicology Forum, the current and potential future science,
regulations, and politics of agricultural biotechnology were presented and discussed. The range of cur-
rent commercial crops and commercial crop traits related to transgenic proteins were reviewed and
example crop traits discussed, including insecticidal resistance conferred by Bt proteins and the devel-
opment of nutritionally enhanced food such as Golden Rice. The existing regulatory framework in the
USA, with an emphasis on US FDA's role in evaluating the safety of genetically engineered crops under
the regulatory umbrella of the FD&C Act was reviewed. Consideration was given to the polarized politics
surrounding agricultural biotechnology, the rise of open access journals, and the inﬂuence of the internet
and social media in shaping public opinion. Numerous questions related to misconceptions regarding
current products and regulations were discussed, highlighting the need for more scientists to take an
active role in public discourse to facilitate public acceptance and adoption of new technologies and to
enable science-based regulations.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction to agricultural biotechnology
The mission of The Toxicology Forum is to encourage open
dialogue on human health and environmental issues that drive
public concerns, academic involvement, industry action and regu-
latory decision making. The dialogue at the meetings facilitates
conﬂict resolution, identiﬁes research gaps, drives research
agendas, and promotes sound regulatory and policy decision
making (The Toxicology Forum, www.toxforum.org). This manu-
script summarizes the ﬁrst half of a day-long session on Agricul-
tural Biotechnology at the 40th Annual Summer Meeting of The
Toxicology Forum, which focused on the history of protein bio-
technologies. Drs. Sherman, Choudhuri, and Vicini presented the
introductory, safety assessment, and communication sections of
this manuscript, respectively.
In order to meet the needs of a growing world population, withApplied Nutrition; FD&C, Act
ety Authority; US FDA, United
lly Modiﬁed Organism; RNAi,
f Agriculture.
.H. Sherman).
Inc. This is an open access article umore afﬂuent consumers, agriculture in the 21st century will need
to overcome many challenges. To sustainably meet the challenges
without bringing millions of acres of new farmland into production
will require considerable increases in yield. Agricultural biotech-
nology is expected to play an important role in sustainably
improving crop yields and improving food security to meet these
needs.
The world population is expected to grow from approximately
seven billion people today to more than nine billion people by 2050
and nearly all of this growth is expected to come from developing
countries (FAO, 2009). In addition, diversion of food supplies to
biofuels production and the adoption of high protein diets by the
expanding middle-class in developing countries are expected to
put further strains on agriculture. Based on projections for global
food demand, we will need to produce more agricultural products
over the next 50 years than in all of human history. Factored into
the projections are population growth, food consumption growth
in developing countries, and a 15% contribution of agricultural
commodities to biofuels in 2050 (Clark, M., 2009). To meet these
needs, without bringing new farmland into production, it is esti-
mated that yields of maize, rice, wheat, and soybean all need to
double by 2050 (Ray et al., 2013). Even with an all-of-the-above
approach to increasing yields that includes improved agronomicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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new conventional pesticides, etc., the challenge to sustainably meet
projected agricultural demands without bringing large tracks of
new farmland into production is signiﬁcant. Current yearly crop
yield improvements of maize, rice, wheat, and soybean average
1.6%, 1.0%, 0.9%, and 1.3%, respectively, which is insufﬁcient to meet
projected needs (Ray et al., 2013).
Biotechnology has already contributed substantially to im-
provements in agriculture. A recent meta-analysis concluded GM
technology has reduced chemical pesticide use by 37%, increased
crop yields by 22%, and increased farmer proﬁts by 68% (Klümper
and Qaim, 2014). The majority of the gains have been realized in
developing countries. To maintain current yields without biotech
crops, it has been estimated that an area larger than the total
farmland planted in the states of Illinois and Indiana would need to
be brought into production (Fig. 1). Although yield depends on
many factors, there are major differences in corn yields observed
between the countries that have adopted new technologies and
those that have not. For example, an analysis of corn yield
improvement rates provided by the USDA PS&D from 2000 to 2008
clearly demonstrate greater yields are observed in those countries
that have embraced agricultural biotechnology (Fig. 2).
The beneﬁts of agricultural biotechnology have resulted in
farmers around the world planting record acreage of biotech crops
in each successive year, since their initial regulatory approvals
nearly 20 years ago. In 2013, approximately 433 million acres of
biotech crops were planted and the acreage planted in non-
industrialized countries has surpassed that planted in industrial-
ized countries (Fig. 3). The trend towards increasing adoption of the
technology is expected to continue, as well as the need for public
dialogue related to the science and politics surrounding the
technology.
2. Introduction to proteins in agricultural biotechnology
(GMOs)
2.1. What is a Genetically Modiﬁed Organism
Essentially all commercial crops are genetically modiﬁed
through one of four techniques (Fig. 4). Traditional breeding is the
most commonmethod of genetic modiﬁcation and almost all cropsFig. 1. Land use beneﬁtshave undergone extensive genetic modiﬁcation through selective
breeding. Chemical or radiation induced mutagenesis increases the
rate at which genes naturally mutate. RNA interference (RNAi) and
transgenesis are achieved through the use of recombinant DNA
technology. As such, using the term Genetically Modiﬁed Organism
(GMO) to describe only plants genetically modiﬁed using modern
biotechnology is somewhat misleading. This is one of the reasons
the FDA does not use the expression “Genetically Modiﬁed (GM)”;
instead FDA uses the expression “Genetically Engineered (GE).”
Traditional plant breeding for modern crops is estimated to involve
the modiﬁcation of 10,000 to greater than 300,000 genes and
commercial introduction of newpatented plant varieties developed
through traditional breeding does not require any safety testing.
Similarly, mutagenesis breeding, which involves indiscriminately
mutating plant seed genes using chemicals or radiation, and then
selecting the plants with the desired newly acquired traits for
further development, potentially involves the genetic modiﬁcation
of thousands of genes. Mutagenesis breeding also does not require
any safety testing before a new plant variety is commercialized. In
contrast, usingmodernbiotechnology, a single newgeneor a limited
numberof genes are inserted into a known location in the genome to
confer a new trait. This form of genetic modiﬁcation requires
extensive safety testing as well as rigorous regulatory review before
commercialization, including: compositional equivalence to
parental crop variety, assessment of potential new metabolites,
chemical nature and function of the newly expressed trait, dietary
exposure levels, similarity of traits to known allergens, toxins or
antinutrient concentrations, effects of conventional food processing
techniques on potential exposures, history of safe exposure, and
assessment of the stability of products in gastric/intestinal ﬂuids
(WHO, 2009). The scientiﬁc justiﬁcation for regulating a genetic
change in a crop based on the method used to generate the change,
rather than on what change was made, is paradoxical.
The extent of genetic modiﬁcation of modern food crops is
exempliﬁed by the Brassica genus of plants. The modern Brassica
cultivars originated from wild cabbage, which is a weedy plant,
through selective breeding. Current species of commercial Brassica
crops are very diverse in both appearance and composition.
Commercially signiﬁcant derivatives include kale, cabbage, cauli-
ﬂower, broccoli, Brussels sprouts, turnips, mustard, and rapeseed/
canola. Yet, all are considered safe based primarily on a history ofof increased yield.
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Fig. 2. Differences in corn yield observed among major producers (at least 10 million metrics of grain/year), based on three year rolling average. National corn yield improvement
rates from 2000 to 2008. Based on data provided by USDA PS&D.
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efforts aimed at developing new traits that include: better nutrient
proﬁles, reduced bitter taste, different fatty acid proﬁles (e.g., lu-
bricants or low trans-fat cooking oils), insect resistance, and
increased yield. These new efforts include the use of biotechnology,
which requires extensive safety testing. Given the targeted nature
of the GE and the random approach of breeding, this is a great
example of the disparity of the safety evidence required for each.Fig. 3. Global Area of Biotech Crops. (James, Clive. 2013. Global Status of Commercialized
permission).2.2. How are transgenic technologies being used in agriculture
The process of developing a new trait using transgenic tech-
nologies has considerably evolved since the ﬁrst transgenic plants
were introduced into commerce approximately 20 year ago. The
ﬁrst step of development involves designing a plasmid vector to
transfer the candidate gene into the crop plant genome, along with
expression elements such as promoters and untranslated regionsBiotech/GM Crops for 2013. ISAAA Brief 46. ISAAA, Ithaca, NY. USA: Reprinted with
Fig. 4. How Crops are Genetically Modiﬁed (Reprinted with Permission from the Genetic Literacy Project).
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efﬁcient transcription, mRNA stability, and translation (Prado et al.,
2014). Often many different candidate genes are tested before
selecting one that can consistently ensure the desired levels of
expression, following introduction into the recipient plant embryo.
The plasmid transfer to plant cells or plant embryos grown in
culture is most often facilitated by Agrobacterium plasmids. After
appropriately transformed cells and embryos are identiﬁed, the
cells are grown into plants. Molecular characterization ensures that
the genetic material is inserted into the genome in a location that
does not disrupt native genes. Traditional breeding techniques,
monitored using molecular markers, are then used to transfer the
transgene from a donor plant variety to commercial plant varieties
optimally developed to grow in different regions of the world.2.3. Bringing a new product to market
Based upon a survey of the largest biotech developers, including
BASF, Bayer CropScience, Dow AgroSciences, DuPont/Pioneer Hi-
Bred, Monsanto and Syngenta AG, the average time between
discovering a new crop trait and its commercialization is approxi-
mately 13 years (McDougall, 2011). Additionally, the time associ-
ated with registration averages 5.5 years and the total cost of
discovery, development and authorization of a new plant biotech-
nology trait introduced between 2008 and 2012 is $136 million
USD. Including researchers, farmers and regulatory specialists, the
process involves more than 4000 professionals. As such, themanpower and costs associatedwith bringing a new biotech trait to
market approaches that needed to bring a new conventional
pesticide or pharmaceutical to market.
In addition to the largest biotech developers identiﬁed above,
there are many other biotech developers who have received regu-
latory approval for biotech crop traits. Included in the list are the
University of Florida, Cornell University, University of Saskatch-
ewan, and Embrapa Brazilian Agricultural Research Corporation.
Over the next decade, the number of corporations, universities, and
governments that receive regulatory approval for commercializa-
tion of biotech crop traits is expected to grow.
Currently, there are eight commercialized biotech crops sold in
the USA including corn, cotton, soy, canola, alfalfa, papaya, sugar
beets and squash. The general types of commercialized traits
include herbicide tolerance (e.g., glyphosate), insect resistance (e.g.,
Lepidopteron species), virus resistance (e.g., ringspot), agronomic
traits (e.g., drought tolerance), and improved nutritional value (e.g.,
high oleic acid and low lineoleic acid, resulting in reduced trans-fat
soybean oil).2.4. Golden Rice: example plant trait
Golden Rice has been developed using biotechnology to help
prevent vitamin A deﬁciency in developing countries. Its identiﬁed
beneﬁts and perceived risks have received considerable press
coverage, both for and against its approval for cultivation, as dis-
cussed below. Considering the polarized politics, ethics of not
1 Use of the term “food” refers to food for humans as well as food for animals.
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it provides an appropriate case study for review. Although rice is
not a biotech crop in the US, it is one of the most promising
improved nutritional value crops, due to its widespread use as a
subsistence crop in Asia, where vitamin A deﬁciency is endemic.
According to the World Health Organization, between 250,000
and 500,000 vitamin A-deﬁcient children become blind every year,
half of them dying within 12 months of losing their sight. Golden
Rice was originally developed at the Swiss Federal Institute of
Technology and the University of Freiburg to supply dietary beta-
carotene to those in need (Ye et al., 2000). Trait improvements
have been made to Golden Rice, notably by Syngenta which
developed Golden Rice 2 (Paine et al., 2005). Golden Rice is engi-
neered to synthesize beta-carotene, which is converted to Vitamin
A in humans, by the insertion of two genes: phytoene synthase
(psy) and carotene desaturase (crtI) which convert geranylgeranyl
diphosphate to beta carotene. Syngenta has arranged royalty-free
access to the patents and intellectual property, held by several
biotechnology companies, for a number of key technologies used in
Golden Rice. This has allowed non-proﬁt organizations such as the
International Rice Research Institute (IRRI) and partners to further
develop Golden Rice.
Support for making Golden Rice freely available in Asia is
widespread and includes diverse moral (e.g., Pope Francis on Nov. 7,
2013; The Golden Rice Project: http://www.goldenrice.org/) and
ﬁnancial support (e.g., Rockefeller Foundation. http://www.
rockefellerfoundation.org/blog/vitamin-deﬁciency-golden-rice-
role; Gates Foundation http://www.gatesfoundation.org/what-we-
do/global-development/agricultural-development/golden-rice).
However, non-governmental organizations (e.g., Greenpeace
http://www.greenpeace.org/international/en/campaigns/
agriculture/problem/genetic-engineering/Greenpeace-and-
Golden-Rice/) have successfully mounted campaigns, based largely
on alleged health concerns, against approvals for planting Golden
Rice in Asia. As such, while the safety of a preventative cure is being
debated, preventable blindness and death continue to plague the
region.
2.5. Cry protein insecticides: example plant trait
Bacillus thuringiensis (Bt) microbial pesticides have a long his-
tory of safe use in both organic farming and agricultural biotech-
nology (more recently reviewed by Koch et al., 2015). Bt is a gram
positive, spore-forming aerobic bacterium that is widely distrib-
uted in soil andwater. Beginning approximately 50 years ago, crude
Bt preparations were sprayed on crops for lepidopteron insect
control and, in agricultural biotechnology, for approximately 15
years various forms of the Bt Cry protein have been transgenically
produced in commercially important crops (Hammond and Koch,
2012).
Insecticidal Cry proteins exist as protoxins and after being
consumed by lepidopteran insect larvae are activated by gut pro-
teases. The activated proteins then bind to speciﬁc receptors on the
gut epithelial cells and cause perforation of the gut membrane. The
epithelial cells then swell and lyse, leading to electrolyte imbalance
and eventually insect death. There is considerable diversity in Bt
proteins, but they all share a commonmode of action (MOA) that is
not operable in humans and other mammals, which lack high af-
ﬁnity gut receptors, and all are proteins with short environmental
half-lives (Hammond and Koch, 2012). Since the proteins rapidly
break down in the environment to peptides and amino acids, res-
idues are of low concern. As such, due to a species-speciﬁcMOA and
lack of environmental persistence, Bt microbial biopesticides are
considered environmental-friendly (OECD, 2007), particularly
when compared to broad spectrum chemical insectides.3. Safety assessment of ﬁrst generation GMOs: evaluation of
submissions under FDA's plant biotechnology consultation
process
The evaluation of biotechnology notiﬁcations under FDA's Plant
Biotechnology Consultation Process was discussed in the presen-
tation. In the United States, GE plants and foods derived from them
are regulated by three federal agencies-the United States Depart-
ment of Agriculture (USDA), the Environmental Protection Agency
(EPA) and the Food and Drug Administration (FDA). While USDA
oversees cultivation and addresses the plant pest issues, EPA
oversees the safe use of pesticidal substances that also includes the
pesticidal proteins in GE plants. FDA evaluates food safety and la-
beling1. FDA's legal authority is derived from the Federal Food Drug
and Cosmetics Act (FD&C Act).
Two Centers of FDA are involved in the safety evaluation of GE
plants and foods derived from them; these are the Center for Food
Safety and Applied Nutrition (CFSAN) that evaluates the safety of
food for consumption by humans, and the Center for Veterinary
Medicine (CVM) that evaluates the safety of food for consumption
by animals. FDA's 1992 Policy Statement on Foods Derived from
New Plant Variety (Federal Register Vol. 57 No. 104 Friday, May 29,
1992 pp. 22,984) provides the framework for the safety evaluation
process. The 1992 policy highlights the scientiﬁc and regulatory
issues related to foods derived from new plant varieties and it also
provides guidance to the industry and recommends consultation
with FDA prior to marketing foods derived from GE plant varieties.
Various sections of the FD&C Act applicable to foods from GE plants
are presented in Table 1.
Developers are encouraged to meet with FDA as part of the
consultation process to discuss the potential safety, nutritional, and
other regulatory issues regarding food from their GE plant variety
under development. During such meetings, the data that have been
generated by the developers are presented to ensure the adequacy
of the data and identify scientiﬁc or regulatory issues that would
need to be resolved prior to marketing. Such meetings and in-
teractions are productive for both the developers and FDA, and they
help the developers prepare and submit the “ﬁnal consultation.”
FDA scientists evaluate this submission as part of the plant
biotechnology consultation process.
FDA uses a multidisciplinary approach to evaluate ﬁnal consul-
tation submissions. In general, ﬁnal consultation submissions often
contain information including a safety assessment of the intro-
duced substance and an assessment of any unintended changes
important to safety or nutrition. This assessment involves a
comprehensive compositional analysis to ascertain whether the
concentrations of any important nutrients, anti-nutrients or toxi-
cants have been changed in away that would be important to safety
or nutrition. Some of the data that are routinely evaluated include
(but are not limited to) the following elements listed in Table 2.
Traditionally molecular characterization relied on Southern blot
analysis, but there may be a trend in utilizing the newer sequencing
techniques in such characterization.
Two early examples of biotechnology-derived products were
discussed. These were: (1) fermentation-derived chymosin pro-
duced in E. coli and (2) the Flavr-Savr tomato. Chymosin produced
in E. coli carrying the bovine prochymosin gene was the ﬁrst food
ingredient produced through GE that was afﬁrmed as GRAS by FDA.
The ﬁrst food from a GE plant considered by FDA was the Flavor-
Savr tomato. The Flavr-Savr tomato expressed a delayed ripening
trait and the kanamycin resistance gene that encodes the enzyme
aminoglycoside-30-phosphotransferase II (APH(30)II), which is a
Table 1
Selected sections of Federal Food, Drug, and Cosmetic Act (FD&C Act) applicable to foods from genetically engineered plants.
Section of FD&C Act Excerpt from FDA's 1992 policy statement
Section 402 “Under section 402(a) (1) of the act, a food is deemed adulterated and thus unlawful if it bears or contains an added poisonous or deleterious
substance that may render the food injurious to health or a naturally occurring substance that is ordinarily injurious.” 57 FR 22,984 at 22,988
Section 403 ”Section 403(i) of the act (21 U.S.C. 343(i)) requires that a producer of a food product describe the product by its common or usual name
or in the absence thereof, an appropriately descriptive term (21 U.S.C. part 101.3) and reveal all facts that are material in light of representations
made or suggested by labeling or with respect to consequences which may result from use (21 U.S.C. 343(a); 21 U.S.C. 321(n)).” 57
FR 22,984 at 22,991
Section 409 “Substances that are expected to become components of food as result of genetic modiﬁcation of a plant and whose composition is such
or has been altered such that the substance is not generally recognized as safe (GRAS) or otherwise exempt are subject to regulation as
“food additives” under section 409 of the act (21 U.S.C. 348). Under the act, substances that are food additives may be used in food only
in accordance with an authorizing regulation.” 57 FR 22,984 at 22,985.
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safety were considered as part of a consultation and it was
concluded that the Flavr-Savr tomato was as safe as other
commonly consumed tomatoes. As part of the safety assessment
the developer submitted a food additive petition for use of APH(30)
II and FDA issued a food additive regulation authorizing its use in
the development of tomato, cotton and canola varieties (21 CFR
173.170).
It was noted that (1) although the biotechnology program re-
mains voluntary, compliance with the law is mandatory and the
food sold in the US has to be safe and in compliance with all reg-
ulatory requirements, (2) the biotechnology consultation process
has been successfully operating for over 20 years, (3) the program
has seen about 150 events and successfully completed over 100
consultations, and (4) the program has become more transparent
over time and has been putting the letters and Note to Files (NTFs)
on the web (http://www.fda.gov/bioconinventory).4. Impact of the food wars on agricultural biotechnology:
communicating the science
The consensus opinion among the most credible scientiﬁc or-
ganizations, such as the nine of the world's Academies of Sciences,
the American Medical Association, The Royal Society of Medicine
and the World Health Organization is that agricultural biotech-
nology poses no additional risks to health than conventional plant
breeding (Genetic Literacy Project, 2014). Globally, plantings ofTable 2
Evaluation of submissions under FDA's plant biotechnology consultation process: comm
Information Explanation
Molecular characterization 1 Source of the new protein (e.g., allergenic or toxic sou
2 Transformation method (e.g., Agrobacterium, Biolistics
3 Selectable markers of transformation
4 Characterization of the insertion event (e.g., identity o
of inserts per integration site, evidence of any truncat
5 Genetic stability of the insert across generations (e.g.,
6 Analysis of the insertgenomic DNA junctions to asse
DNA junctions were created during transformation an
7 Characterization of the expressed protein (e.g., N-term
denaturing gel electrophoretic analysis (SDS-PAGE) fo
glycosylation analysis)
Allergenicity and toxicity 1 Bioinformatic analysis of the protein sequence to show
the expressed protein and known allergens (e.g., >35%
amino acids in the expressed protein)
2 Digestibility of the protein by simulated gastric ﬂuid (
3 Bioinformatic analysis to determine whether the prote
4 Acute toxicity study in mice to determine whether the
5 Knowledge about the source of the protein also helps
Composition analysis 1 Compositional analysis of key nutrients and key anti-n
and harvested under the same conditions provides da
anti-nutrients or toxicants have been changed in a wa
ﬁber, ash, moisture, amino acids, fatty acids, vitamins,biotech crops continue to increase by double-digit percentages
every year, due to beneﬁts provided to farmers (James, 2013). But in
spite of the consensus of science and the popularity among farmers,
there is a continued debate in society about their beneﬁts and
safety. Part of the explanation for these seemingly unrelated trends
is that agriculture and food are at the center of some of the world's
biggest challenges. People are bombarded daily with recommen-
dations on diet fads and supplements while climate change, pop-
ulation growth and availability of natural resources, such as arable
land, threaten food security. At the same time, the internet and
social media have increased access to information/misinformation.
It is no wonder the public is confused when they are subjected to
publication, retraction and republication of a manuscript, such as a
recent manuscript that claimed to demonstrate that genetically
engineered crops cause cancer (Seralini et al., 2012), or the publi-
cation and retraction of the claimed link between vaccines and
autism (Deer, 2011; Wakeﬁeld et al., 1998).
It becomes even more difﬁcult for consumers to judge good and
bad science when the quantity of accessible information is ex-
ploding. In the last 20 years, the number of science journal articles
has doubled, mostly due to increased number of open access
journals. This obviously increases pressure on good scientists for
spending an increasing amount of time doing peer reviews and is
resulting in more superﬁcial peer-reviews by other scientists (Arns,
2014). One animal study (Seralini et al., 2012), that was published in
an established journal, had obvious ﬂaws in the study design and
statistical analysis resulting in critical reviews having to beonly received data and information.
rce, plant, microbial, viral, synthetic)
);
f the inserted DNA, number of integration sites in the genome, number
ed insert etc.)
assessment of structural integrity, and Mendelian inheritance pattern)
ss whether any “putative open reading frames” across the insert-genomic
d whether they are likely to represent a safety concern.
inal sequencing, mass spectrometric analysis to generate tryptic peptide map,
r molecular weight determination, immunoreactivity assessment,
that there is no immunologically relevant sequence identity between
identity in a sliding window of 80 amino acids, and identity of 8 contiguous
sometimes by simulated intestinal ﬂuid also)
in has any meaningful identity to known protein toxin sequence;
protein could be acutely toxic by oral consumption
evaluate the protein for its putative allergenicity and toxicity potential.
utrients in food from the GE plants and their conventional counterparts grown
ta and information to assess whether the levels of any important nutrients,
y that would be important to safety or nutrition (e.g., protein, fat, carbohydrates,
and anti-nutrients).
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agencies (EFSA, 2012; FSANZ, 2012). Another animal study (Carman
et al., 2013) was published in a journal that primarily has editorial
board members with experience in marketing or soil science. The
study conduct or review would have greatly beneﬁted from tech-
nical contributions from an animal scientist, veterinary pathologist
or toxicologist. But, other “study” results have been reported on
web sites with no peer review. One such site reported a “stunning
corn comparison” suggesting low nutrient concentrations of GM
corn even though there was no protein or carbohydrate reported
and total organic matter was 2% (Mom's Across America, http://
www.momsacrossamerica.com/stunning_corn_comparison_gmo_
versus_non_gmo), ﬁndings which are incompatible with any
known corn variety (GM or other). The website owner would not
concede that the data was likely from soil when this was appro-
priately suggested on the site's comments.
Another source of public confusion often results from the difﬁ-
culty of those not trained in science to distinguish the difference
between correlation and causation, as well as the willingness of
some to capitalize on that confusion. For example, a recent publi-
cation drew an unsubstantiated causative link between the simple
correlation of celiac disease and increased use of glyphosate
(Samsel and Seneff, 2013). This is similar to concluding that organic
food causes autism, since there is a strong correlation (R ¼ 0.9971)
between the rise in the incidence of autism and the rise in organic
food sales (IMGUR, http://imgur.com/1WZ6h), although no one
expects organic food to be causative.
Considering the above, it becomes clear that industry and aca-
demic scientists need to communicate sciencemore broadly or they
will be left out of the public conversation. Additionally, the advent
of the internet and social media has changed how we need to
communicate the science to the public. If industry and afﬁliated
organizations don't get the communications right, then public
opinion will be swayed by those with more aggressive internet
communications, regardless of the accuracy of the information
communicated. As part of an industry effort to improve public
communication, the six major biotech companies along with a
biotech industry organization, Council for Biotechnology Informa-
tion (Washington, DC), have started a website to answer questions
about crop biotechnology in a more consumer-friendly manner
(http://www.gmoanswers.com). Many questions are answered by
non-industry scientiﬁc experts; however, questions about business
practices are asked as frequently as questions about science. Those
business questions are generally answered by industry.
Overall, more scientists need to take an active role in public
discourse to enable science-based regulations and to facilitate
public acceptance and adoption of new technologies. This will
become evenmore important with newer technologies that may be
less familiar to non-scientists.5. Discussion2
Several of the meeting participants noted that the public debate
over GMOs made it hard for them to separate fact from ﬁction and
that after listening to the presentations they recognized their own
misconceptions. A participant commented that the Golden Rice
story highlighted the promise of agricultural biotechnology to help
meet nutritional needs in developing countries and had heard that
there were also philanthropic efforts being made to develop salt
tolerant crops. In response, the Water Efﬁcient Maize for Africa2 This paper is intended to describe the questions and views expressed at the
meeting, but those views may not necessarily be those of all the authors and/or
their employers.(WEMA) project was discussed. It is a public/private partnership led
by the Kenyan-based African Agricultural Technology Foundation
and funded by the Bill and Melinda Gates Foundation, Howard G.
Buffet Foundation, and USAID with the goal of developing water-
efﬁcient corn varieties and providing them royalty free to small-
holder farmers to enhance food security in Sub-Saharan Africa
(http://wema.aatf-africa.org/). Some of the corn hybrids developed
by WEMA have already been made available to African farmers.
Monsanto's contributions have included providing maize germ-
plasm to enable conventional breeding efforts, offering technical
expertise to develop regionally adapted hybrids, and donating its
commercial drought-tolerance and insect protection traits royalty-
free to all seed companies in Africa (Monsanto Company, http://
news.monsanto.com/video/water-efﬁcient-maize-africa).
A participant asked if industry puts animal genes in plants.
Although there are no speciﬁc laws preventing the use of animal
genes in developing new plant varieties, it is general industry
policy not to transgenically insert genes that produce animal-
speciﬁc proteins into crops because of the potential for negative
public perception.
Several participants asked for clariﬁcation regarding the regu-
latory approval of GM crops in the EU, as they thought there was a
ban on GM crops in Europe. Only one GM crop, MON810 corn, is
currently approved for commercial cultivation and is being culti-
vated in the EU. MON810 denotes a Bt insecticidal trait that targets
Lepidoptera insects, including the European Corn Borer which is
difﬁcult to control with conventional pesticides. BASF received
cultivation approval for a GM potato (Amﬂora), but it is not
currently being cultivated in the EU. However, approximately 50
GM crops have been approved for import into the EU. Additionally,
the scientiﬁc bodies charged with assessing the safety of GMO
crops have never found a health concern related to these crops (for
more information EFSA GM crop assessments are publically avail-
able at EFSA Publications, http://www.efsa.europa.eu/en/
publications.htm). The European Commission, which is the execu-
tive body responsible for coordinating the EU approval process and
issuing ﬁnal approvals if Member States fail to act, has not pro-
gressed pending cultivation applications through the European
decisionmaking process. For over a year, the European Commission
has put on hold the authorization of genetically modiﬁed (GM)
crops for import, resulting in 58 GM applications for import
pending in the EU system, of which 18 have already completed the
EFSA risk assessment (Europa Bio, http://www.europabio.org/sites/
default/ﬁles/position/undue_delays_update_january_2015_ﬁnal.
pdf).
One participant asked the FDA speaker why chronic studies are
not required for GM proteins or crops. Protein toxins are acutely
toxic through systemic exposure (Shiga et al., 2006; Zhao et al.,
2013) and proteins known to be toxic through the oral route
generally cause acute adverse effects. Therefore, an acute oral
toxicity study is generally considered sufﬁcient to help identify the
toxic potential of orally consumed proteins (Sjoblad et al., 1992;
Miyake et al., 2007; Hammond et al., 2013). Furthermore,
knowing the biological function of a transgenic protein is helpful
when assessing its potential for causing toxicity. Therefore, when
needed, shorter-term toxicity studies are appropriate for proteins,
along with information conﬁrming their digestibility, information
regarding their biological function, and a bioinformatics analysis
for putative toxicity/allergenicity alerts. Additionally, unlike some
conventional pesticides which can be metabolized and/or degrade
into chemicals that can bioaccumulate and/or be more toxic than
the parent compound, proteins break down into peptides and
amino acids in the gut and are absorbed as nutrients. Currently,
subchronic studies with the plant-expressed transgenic protein
and/or the crop commodity (e.g., corn and soybean seed) are
J.H. Sherman et al. / Regulatory Toxicology and Pharmacology 73 (2015) 811e818818required by select regulatory agencies around the world, but no
regulatory agency requires chronic testing of GMOs.
The labeling of GMOs was brought up by a participant who
commented that labeling is done in different countries, including
Brazil, and does not present challenges in the countries in which it
has been mandated. The question was then raised: why don't US
companies support GMO labeling? Monsanto and most other
companies support voluntary labeling. Per FDA guidance, manda-
tory labeling has not been required for method of production and is
only required for nutritional information or when there are
meaningful health or nutritional differences between products.
With the exception of nutritionally improved reduced trans-fat
grains, to date, there are no examples where the data submitted
as part of the GM crop approval process demonstrates a meaningful
difference in health or nutrition of the transgenic crop when
compared to its parental variety.
There were questions related to seeking to understand if FDA
CFSAN interacts with and/or coordinates the review process with
EPA and/or FDA. Although there is no formal process for coordi-
nating reviews, FDA periodically has teleconference calls to discuss
various biotech issues with USEPA and USDA. FDA also coordinates
the review of notices with EPA and USDA, if there are questions/
issues that need to be addressed.
One suggestion for improvement of the entire agricultural
biotechnology session was to include an NGO in program at future
meeting. The speakers generally thought this would be a good idea,
so that the audience would have a more complete picture of the
political and scientiﬁc issues that are driving adoption of the tech-
nologies. The speakers, as well as representatives from The Toxi-
cology Forum thought thiswas appropriate and if a follow-up session
is held in the future would try to include a NGO in the program.
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